|
|
 Previous Article | Table of Contents | Next Article 
Syngeneic transplantation with peripheral blood mononuclear cells collected
after the administration of recombinant human granulocyte
colony-stimulating factor
CH Weaver, CD Buckner, K Longin, FR Appelbaum, S Rowley, K Lilleby, J Miser, R Storb, JA Hansen and W Bensinger
Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
Five syngeneic transplants were performed in four patients following
myeloablative therapy using unmodified peripheral blood mononuclear cells
(PBMCs) collected after the administration of recombinant human granulocyte
colony stimulating factor (rhG-CSF) to normal donors. The only toxicity
experienced by the four normal donors was bone pain. Four patients received
two collections of PBMCs, and a second transplant was performed in one
patient with one collection. The patients received a median of 20.53 x
10(8) total nucleated cells/kg (range 20 to 25.5), 11.3 x 10(8) total
mononuclear cells/kg (range 6.52 to 17.2), 113.1 x 10(4)/kg CFU-GM (range
46.7 to 211.8) and 9.6 x 10(6) CD34+ cells/kg (range 1.6 to 12.6)
Post-transplant growth factors were not administered. The median time to an
absolute neutrophil count greater than 0.5 x 10(9)/L was 14 days (range 10
to 18). The median time to platelet transfusion independence was 11 days
(range 10 to 13). Two patients had the number of CD3+ T lymphocytes
determined in the pheresis product. An average of 3.04 x 10(10) CD3+ cells
were collected per pheresis. This represents an approximate 1 log increase
over the number of T lymphocytes in a typical bone marrow transplant.
Rh-GCSF can be used to mobilize peripheral blood progenitor cells from
normal donors with minimal toxicity. Studies of allogeneic transplants
using PBMCs collected after rhG-CSF administration to determine permanent
grafting ability and the incidence and severity of graft-versus-host
disease are warranted.
Volume 82,
Issue 7,
pp. 1981-1984,
10/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K.-J. Tsai, Y.-C. Tsai, and C.-K. J. Shen
G-CSF rescues the memory impairment of animal models of Alzheimer's disease
J. Exp. Med.,
June 11, 2007;
204(6):
1273 - 1280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-C. Shyu, S.-Z. Lin, C.-C. Lee, D. D. Liu, and H. Li
Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial
Can. Med. Assoc. J.,
March 28, 2006;
174(7):
927 - 933.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-C. Shyu, S.-Z. Lin, H.-I Yang, Y.-S. Tzeng, C.-Y. Pang, P.-S. Yen, and H. Li
Functional Recovery of Stroke Rats Induced by Granulocyte Colony-Stimulating Factor-Stimulated Stem Cells
Circulation,
September 28, 2004;
110(13):
1847 - 1854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Bishop, S. R. Tarantolo, R. B. Geller, J. C. Lynch, P. J. Bierman, Z. S. Pavletic, J. M. Vose, S. Kruse, S. P. Dix, M. E. Morris, et al.
A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation
Blood,
July 1, 2000;
96(1):
80 - 85.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Drize, J. Chertkov, E. Sadovnikova, S. Tiessen, and A. Zander
Long-Term Maintenance of Hematopoiesis in Irradiated Mice by Retrovirally Transduced Peripheral Blood Stem Cells
Blood,
March 1, 1997;
89(5):
1811 - 1817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
